Age-Dependent Neutralization of SARS-CoV-2 and P.1 Variant by Vaccine Immune Serum Samples

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592 · see citing works

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119 · see citing works

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

Khoury, D. S., Cromer, D., Reynaldi, A., Schlub, T. E., Wheatley, A. K., Juno, J. A., Subbarao, K., Kent, S. J., Triccas, J. A., & Davenport, M. P. (2021) · Nature Medicine · doi:10.1038/s41591-021-01377-8 · Cited by 3,742 · see citing works

Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data

Haas, E. J., Angulo, F. J., McLaughlin, J. M., Anis, E., Singer, S. R., Khan, F., Brooks, N., Smaja, M., Mircus, G., Pan, K., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00947-8 · Cited by 1,564 · see citing works

COVID-19 Vaccine Breakthrough Infections Reported to CDC — United States, January 1–April 30, 2021

CDC COVID-19 Vaccine Breakthrough Case Investigations Team, CDC COVID-19 Vaccine Breakthrough Case Investigations Team, Birhane, M., Bressler, S., Chang, G., Clark, T., Dorough, L., Fischer, M., Watkins, L. F., Goldstein, J. M., et al. (2021) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7021e3 · Cited by 421 · see citing works

Excess mortality in england and wales during the first wave of the COVID-19 pandemic

Kontopantelis, E., Mamas, M. A., Deanfield, J., Asaria, M., & Doran, T. (2021) · Journal of Epidemiology and Community Health · doi:10.1136/jech-2020-214764 · Cited by 121 · see citing works

Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months

Levin, E. G., Lustig, Y., Cohen, C., Fluss, R., Indenbaum, V., Amit, S., Doolman, R., Asraf, K., Mendelson, E., Ziv, A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2114583 · Cited by 1,703 · see citing works

Vaccination before or after SARS-CoV-2 infection leads to robust humoral response and antibodies that effectively neutralize variants

Bates, T. A., McBride, S. K., Leier, H. C., Guzman, G., Lyski, Z. L., Schoen, D., Winders, B., Lee, J., Lee, D. X., Messer, W. B., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abn8014 · Cited by 303 · see citing works

Population antibody responses following COVID-19 vaccination in 212,102 individuals

Ward, H., Whitaker, M. D., Flower, B., Tang, S. N., Atchison, C. J., Darzi, A. W., Donnelly, C. A., Cann, A., Diggle, P. J., Ashby, D., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28527-x · Cited by 169 · see citing works

Willingness to Receive the Booster COVID-19 Vaccine Dose in Poland

Rzymski, P., Poniedziałek, B., & Fal, A. (2021) · Vaccines · doi:10.3390/vaccines9111286 · Cited by 160 · see citing works

The Delta and Omicron Variants of SARS-CoV-2: What We Know So Far

Chavda, V. P., Bezbaruah, R., Deka, K., Nongrang, L., & Kalita, T. (2022) · Vaccines · doi:10.3390/vaccines10111926 · Cited by 103 · see citing works

Neutralization capacity of antibodies elicited through homologous or heterologous infection or vaccination against SARS-CoV-2 VOCs

Bekliz, M., Adea, K., Vetter, P., Eberhardt, C. S., Hosszu-Fellous, K., Vu, D., Puhach, O., Essaidi-Laziosi, M., Waldvogel‐Abramowski, S., Stephan, C., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31556-1 · Cited by 85 · see citing works

Role of Senescence and Aging in SARS-CoV-2 Infection and COVID-19 Disease

Lynch, S. M., Guo, G., Gibson, D. S., Bjourson, A. J., & Singh, T. (2021) · Cells · doi:10.3390/cells10123367 · Cited by 69 · see citing works

Anti-SARS-CoV-2 antibodies elicited by COVID-19 mRNA vaccine exhibit a unique glycosylation pattern

Farkash, I., Feferman, T., Saban, N. C., Avraham, Y., Morgenstern, D., Mayuni, G., Barth, N., Lustig, Y., Miller, L., Shouval, D. S., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.110114 · Cited by 60 · see citing works

Epidemiology and Clinical Presentation of COVID-19 in Older Adults

Abul, Y., Leeder, C., & Gravenstein, S. (2022) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2025.09.007 · Cited by 63 · see citing works

Characteristics associated with serological COVID-19 vaccine response and durability in an older population with significant comorbidity: the Danish Nationwide ENFORCE Study

Søgaard, O. S., Reekie, J., Johansen, I. S., Nielsen, H., Benfield, T., Wiese, L., Stærke, N. B., Iversen, K. K., Fogh, K., Bodilsen, J., et al. (2022) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2022.03.003 · Cited by 59 · see citing works

Association of Frailty, Age, and Biological Sex With Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccine–Induced Immunity in Older Adults

Shapiro, J. R., Sitaras, I., Park, H. S., Aytenfisu, T. Y., Caputo, C. A., Li, M., Lee, J., Johnston, T. S., Li, H., Wouters, C., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac397 · Cited by 55 · see citing works

The Third dose of CoronVac vaccination induces broad and potent adaptive immune responses that recognize SARS-CoV-2 Delta and Omicron variants

Chen, Y., Chen, L., Yin, S., Tao, Y., Zhu, L., Tong, X., Mao, M., Li, M., Wan, Y., Ni, J., et al. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2081614 · Cited by 55 · see citing works

An extended interval between vaccination and infection enhances hybrid immunity against SARS-CoV-2 variants

Bates, T. A., Leier, H. C., McBride, S. K., Schoen, D., Lyski, Z. L., Lee, D. X., Messer, W. B., Curlin, M. E., & Tafesse, F. (2023) · JCI Insight · doi:10.1172/jci.insight.165265 · Cited by 55 · see citing works

Waning effectiveness of SARS-CoV-2 mRNA vaccines in older adults: a rapid review

Nanishi, E., Levy, O., & Ozonoff, A. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2045857 · Cited by 46 · see citing works

Geroscience

Kritchevsky, S. B., & Cummings, S. R. (2025) · JAMA · doi:10.1001/jama.2025.11289 · Cited by 38 · see citing works

BNT162b2-induced neutralizing and non-neutralizing antibody functions against SARS-CoV-2 diminish with age

Bates, T. A., Lu, P., Kang, Y. J., Schoen, D., Thornton, M. A., McBride, S. K., Park, C., Kim, D., Messer, W. B., Curlin, M. E., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111544 · Cited by 32 · see citing works

A potent alpaca-derived nanobody that neutralizes SARS-CoV-2 variants

Weinstein, J. B., Bates, T. A., Leier, H. C., McBride, S. K., Barklis, E., & Tafesse, F. (2022) · iScience · doi:10.1016/j.isci.2022.103960 · Cited by 32 · see citing works

Predictors of long-term neutralizing antibody titers following COVID-19 vaccination by three vaccine types: the BOOST study

Prather, A. A., Dutcher, E. G., Robinson, J. E., Lin, J., Blackburn, E. H., Hecht, F. M., Mason, A. E., Fromer, E., Merino, B., Frazier, R., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-33320-x · Cited by 31 · see citing works

Reactogenicity and Immunogenicity of the Pfizer and AstraZeneca COVID-19 Vaccines

Mahallawi, W. H., & Mumena, W. A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.794642 · Cited by 30 · see citing works

Neutralization against Omicron subvariants after BA.5/BF.7 breakthrough infection weakened as virus evolution and aging despite repeated prototype-based vaccination 1

Wang, H., Xue, Q., Zhang, H. C., Yuan, G., Wang, X., Sheng, K., Li, C., Cai, J., Sun, Y., Zhao, J., et al. (2023) · Emerging Microbes & Infections · doi:10.1080/22221751.2023.2249121 · Cited by 30 · see citing works

Humoral Response to BNT162b2 Vaccine Against SARS-CoV-2 Variants Decays After Six Months

Lopera, T. J., Chvatal‐Medina, M., Flórez‐Álvarez, L., Zapata-Cardona, M. I., Taborda, N. A., Rugeles, M. T., & Hernández, J. C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.879036 · Cited by 29 · see citing works

Reduced Antibody Acquisition with Increasing Age following Vaccination with BNT162b2: Results from Two Longitudinal Cohort Studies in The Netherlands

van den Hoogen, L. L., Boer, M. C., Postema, A., de Rond, L., de Zeeuw‐Brouwer, M., Pronk, I., Wijmenga‐Monsuur, A. J., Bijvank, E., Kruiper, C., Beckers, L., et al. (2022) · Vaccines · doi:10.3390/vaccines10091480 · Cited by 24 · see citing works

Molecular Level Dissection of Critical Spike Mutations in SARS‐CoV‐2 Variants of Concern (VOCs): A Simplified Review

Joshi, N., Tyagi, A., & Nigam, S. (2021) · ChemistrySelect · doi:10.1002/slct.202102074 · Cited by 20 · see citing works

SARS-CoV-2 booster vaccine dose significantly extends humoral immune response half-life beyond the primary series

Korosec, C. S., Dick, D. W., Moyles, I. R., & Watmough, J. (2024) · Scientific Reports · doi:10.1038/s41598-024-58811-3 · Cited by 26 · see citing works

Omicron neutralizing antibody response following booster vaccination compared with breakthrough infection

Curlin, M. E., Bates, T. A., Guzman, G., Schoen, D., McBride, S. K., Carpenter, S. D., & Tafesse, F. (2022) · Med · doi:10.1016/j.medj.2022.09.001 · Cited by 20 · see citing works

Mucosal chemokine adjuvant enhances synDNA vaccine-mediated responses to SARS-CoV-2 and provides heterologous protection in vivo

Gary, E. N., Tursi, N. J., Warner, B. M., Parzych, E. M., Ali, A., Frase, D. M., Moffat, E., Embury‐Hyatt, C., Smith, T. R. F., Broderick, K. E., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100693 · Cited by 18 · see citing works

Demographic and Clinical Factors Associated With Anti–SARS-CoV-2 Antibody Levels After 2 BNT162b2 mRNA Vaccine Doses

Nam, S. Y., Jeon, S. W., Lee, H. S., Lim, H. J., Lee, D. W., & Yoo, S. S. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.12996 · Cited by 16 · see citing works

Diverging Maternal and Cord Antibody Functions From SARS-CoV-2 Infection and Vaccination in Pregnancy

Adhikari, E. H., Lu, P., Kang, Y. J., McDonald, A. R., Pruszynski, J. E., Bates, T. A., McBride, S. K., Trank-Greene, M., Tafesse, F., & Lu, L. L. (2023) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiad421 · Cited by 14 · see citing works

The public’s attitude to and acceptance of periodic doses of the COVID-19 vaccine: A survey from Jordan

Abuhammad, S., Khabour, O. F., Alzoubi, K. H., Hamaideh, S. H., Alzoubi, B. A., Telfah, W. S., & El-zubi, F. K. (2022) · PLoS ONE · doi:10.1371/journal.pone.0271625 · Cited by 16 · see citing works

Immune evasion and chronological decrease in titer of neutralizing antibody against SARS-CoV-2 and its variants of concerns in COVID-19 patients

Takeshita, M., Nishina, N., Moriyama, S., Takahashi, Y., Ishii, M., Saya, H., Kondo, Y., Kaneko, Y., Suzuki, K., Fukunaga, K., et al. (2022) · Clinical Immunology · doi:10.1016/j.clim.2022.108999 · Cited by 12 · see citing works

Adenosine deaminase augments SARS-CoV-2 specific cellular and humoral responses in aged mouse models of immunization and challenge

Gary, E. N., Tursi, N. J., Warner, B. M., Cuismano, G., Connors, J. R., Parzych, E. M., Griffin, B. D., Bell, M. R., Ali, A., Frase, D. M., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1138609 · Cited by 13 · see citing works

Nucleic acid vaccines: innovations, efficacy, and applications in at-risk populations

Konopka, E., Edgerton, A. O., & Kutzler, M. A. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1584876 · Cited by 13 · see citing works

Definition of factors associated with negative antibody response after COVID-19 vaccination in patients with hematological diseases

Rotterdam, J., Thiaucourt, M., Weiß, C., Schwaab, J., Reiter, A., Kreil, S., Steiner, L., Fenchel, S., Popp, H. D., Hofmann, W., et al. (2022) · Annals of Hematology · doi:10.1007/s00277-022-04866-z · Cited by 13 · see citing works

Evaluation of antibody kinetics and durability in healthy individuals vaccinated with inactivated COVID-19 vaccine (CoronaVac): A cross-sectional and cohort study in Zhejiang, China

Zhang, H., Hua, Q., Xu, N., Zhang, X., Chen, B., Xi-jun, M., Hu, J., Chen, Z., Yu, P., Lei, H., et al. (2023) · eLife · doi:10.7554/elife.84056 · Cited by 14 · see citing works

Roadmap for Sex-Responsive Influenza and COVID-19 Vaccine Research in Older Adults

Shapiro, J. R., Morgan, R., Leng, S. X., & Klein, S. L. (2022) · Frontiers in Aging · doi:10.3389/fragi.2022.836642 · Cited by 12 · see citing works

Longitudinal study of humoral immunity against SARS-CoV-2 of health professionals in Brazil: the impact of booster dose and reinfection on antibody dynamics

Franco-Luiz, A. P. M., Fernandes, N. M. G. S., Silva, T. B. D. S., Bernardes, W. P. D. O. S., Westin, M. R., Santos, T. G., Fernandes, G. D. R., Simões, T. C., Silva, E. F. E., Gava, S. G., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1220600 · Cited by 12 · see citing works

Prevalence of SARS-CoV-2 antibodies among Belgian nursing home residents and staff during the primary COVID-19 vaccination campaign

Meyers, E., Rop, L. D., Deschepper, E., Duysburgh, E., Burghgraeve, T. D., Ngoc, P. V., Digregorio, M., Delogne, S., Coen, A., Clercq, N. D., et al. (2022) · European Journal of General Practice · doi:10.1080/13814788.2022.2149732 · Cited by 12 · see citing works

COVID-19 vaccine antibody responses in community-dwelling adults to 48 weeks post primary vaccine series

Walmsley, S. L., Szadkowski, L., Wouters, B. G., Clarke, R., Colwill, K., Rochon, P. A., Brudno, M., Ravindran, R., Raboud, J., McGeer, A., et al. (2023) · iScience · doi:10.1016/j.isci.2023.106506 · Cited by 11 · see citing works

Neutralizing antibody responses and cellular responses against SARS-CoV-2 Omicron subvariants after mRNA SARS-CoV-2 vaccination in kidney transplant recipients

Kawashiro, K., Suzuki, R., Nogimori, T., Tsujino, S., Iwahara, N., Hirose, T., Okada, K., Yamamoto, T., Fukuhara, T., Hotta, K., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-63147-z · Cited by 10 · see citing works

Fully understanding the efficacy profile of the COVID-19 vaccination and its associated factors in multiple real-world settings

Panahi, Y., Einollahi, B., Beiraghdar, F., Darvishi, M., Fathi, S., Javanbakht, M., Shafiee, S., & Akhavan‐Sigari, R. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.947602 · Cited by 10 · see citing works

Hybrid immunity in older adults is associated with reduced SARS-CoV-2 infections following BNT162b2 COVID-19 immunisation

Pallett, S. J. C., Heskin, J., Keating, F., Mazzella, A., Taylor, H., Patel, A. M., Lamb, G., Sturdy, D., Eisler, N., Denny, S., et al. (2023) · Communications Medicine · doi:10.1038/s43856-023-00303-y · Cited by 10 · see citing works

Declining Levels of Neutralizing Antibodies to SARS-CoV-2 Omicron Variants Are Enhanced by Hybrid Immunity and Original/Omicron Bivalent Vaccination

Walmsley, S. L., Nabipoor, M., Qi, F., Lovblom, L. E., Ravindran, R., Colwill, K., Dayam, R. M., Tursun, T. R., Silva, A., Gingras, A., et al. (2024) · Vaccines · doi:10.3390/vaccines12060564 · Cited by 10 · see citing works

Vaccine Type-, Age- and Past Infection-Dependence of the Humoral Response to SARS-CoV-2 Spike S Protein

Romero-Pinedo, S., Quesada, M., Horndler, L., Álvarez-Fernández, S., Olmo, A., Abia, D., Alarcón, B., & Delgado, P. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.809285 · Cited by 8 · see citing works

Analysis of Factors Affecting Neutralizing Antibody Production after COVID-19 Vaccination Using Newly Developed Rapid Point-of-Care Test

Shim, H. W., Shin, J. H., Shin, S. C., Lee, H. J., So, K. S., Lee, S. Y., Jun, J. W., Seo, J. K., Lee, H. S., Lee, S. Y., et al. (2022) · Diagnostics · doi:10.3390/diagnostics12081924 · Cited by 9 · see citing works

Factors associated with neutralizing antibody levels induced by two inactivated COVID-19 vaccines for 12 months after primary series vaccination

Wang, F., Huang, B., Lv, H., Feng, L., Ren, W., Wang, X., Tang, L., Liu, Q., Wu, D., Zheng, H., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.967051 · Cited by 10 · see citing works

The bullwhip effect, T-cell telomeres, and SARS-CoV-2

Aviv, A. (2022) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(22)00190-8 · Cited by 9 · see citing works

Comparison of BNT162b2-, mRNA-1273- and Ad26.COV2.S-Elicited IgG and Neutralizing Titers against SARS-CoV-2 and Its Variants

Padhiar, N. H., Liu, J., Wang, X., Wang, X., Bodnar, B. H., Khan, S., Wang, P., Khan, A. I., Luo, J. J., Hu, W., et al. (2022) · Vaccines · doi:10.3390/vaccines10060858 · Cited by 8 · see citing works

Technology-assisted adaptive recruitment strategy for a large nation-wide COVID-19 vaccine immunogenicity study in Brunei

Shim, C. Y., Chan, S. Y., Wei, Y., Ghani, H., Ahmad, L., Sharif, H., Alikhan, M. F., Bagol, S. H., Taib, S., Tan, C. W., et al. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.983571 · Cited by 12 · see citing works

Six-Month Follow-Up of Immune Responses after a Rapid Mass Vaccination against SARS-CoV-2 with BNT162b2 in the District of Schwaz/Austria

Bánki, Z., Seekircher, L., Falkensammer, B., Bante, D., Schäfer, H., Harthaller, T., Kimpel, J., Willeit, P., von Laer, D., & Borena, W. (2022) · Viruses · doi:10.3390/v14081642 · Cited by 8 · see citing works

SARS-CoV-2 neutralizing antibody response in vaccinated and non-vaccinated hospital healthcare workers with or without history of infection

Jacot, D., von Rotz, U., Pellaton, C., Blondet, F., Aebischer, O., Perreau, M., Rham, M. D., Pantaleo, G., Marchetti, O., & Greub, G. (2022) · Microbes and Infection · doi:10.1016/j.micinf.2022.105077 · Cited by 8 · see citing works

Quantifying the Vaccine-Induced Humoral Immune Response to Spike-Receptor Binding Domain as a Surrogate for Neutralization Testing Following mRNA-1273 (Spikevax) Vaccination Against COVID-19

Kirste, I., Hortsch, S., Grunert, V. P., Legault, H. M., Maglinao, M., Eichenlaub, U., Kashlan, B., Pajón, R., & Jochum, S. (2022) · Infectious Diseases and Therapy · doi:10.1007/s40121-022-00711-y · Cited by 8 · see citing works

Dynamics of anti-SARS-CoV-2 IgG antibody responses following breakthrough infection and the predicted protective efficacy: A longitudinal community-based population study in China

Yan, X., Zhao, X., Du, Y., Wang, H., Liu, L., Wang, Q., Liu, J., & Wei, S. (2024) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2024.107075 · Cited by 8 · see citing works

Dynamics of neutralizing antibodies against COVID-19 Omicron subvariants following breakthrough infection in southwest China between December 2022 and April 2024

He, Y., Yin, Y., Zhang, Y., Yang, H., Jiang, Z., Fang, H., Zhao, T., Liu, X., Liu, Y., Zeng, Y., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02319-3 · Cited by 7 · see citing works

T cell hybrid immunity against SARS-CoV-2 in children: a longitudinal study

Qui, M., Hariharaputran, S., Hang, S. K., Zhang, J., Tan, C. W., Chong, C. Y., Low, J. G. H., Wang, L., Bertoletti, A., Yung, C. F., et al. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105203 · Cited by 7 · see citing works

Assessing the Reliability of SARS-CoV-2 Neutralization Studies That Use Post-Vaccination Sera

Jacobsen, H., Sitaras, I., Jurgensmeyer, M., Mulders, M. N., Goldblatt, D., Feikin, D. R., Bar‐Zeev, N., Higdon, M. M., & Knoll, M. D. (2022) · Vaccines · doi:10.3390/vaccines10060850 · Cited by 7 · see citing works

Neutralizing Antibody Activity to Severe Acute Respiratory Syndrome Coronavirus 2 Delta (B.1.617.2) and Omicron (B.1.1.529) After 1 or 2 Doses of BNT162b2 Vaccine in Infection-Naive and Previously Infected Individuals

Moy, J. N., Anderson, M., Shen, X., Fu, J., Stec, M., Gosha, A., Naquiallah, D., Kinslow, J. D., Montefiori, D. C., Cloherty, G., et al. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac261 · Cited by 7 · see citing works

Strong Neutralizing Antibody Responses to SARS-CoV-2 Variants Following a Single Vaccine Dose in Subjects With Previous SARS-CoV-2 Infection

Ekström, N., Haveri, A., Solastie, A., Virta, C., Österlund, P., Nohynek, H., Nieminen, T. A., Ivaska, L., Tähtinen, P. A., Lempainen, J., et al. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac625 · Cited by 7 · see citing works

COVID-19 Vaccines—All You Want to Know

Shishido, A. A., Barnes, A. H., Narayanan, S., & Chua, J. V. (2023) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0042-1759779 · Cited by 6 · see citing works

Immunogenicity of Pfizer mRNA COVID-19 Vaccination Followed by J&J Adenovirus COVID-19 Vaccination in Two Patients with Chronic Lymphocytic Leukemia

Lyski, Z. L., Kim, M. S., Lee, D. X., Sampson, D. A., Raué, H.-P., Raghunathan, V. M., Ryan, D., Brunton, A. E., Slifka, M. K., Messer, W. B., et al. (2022) · Case Reports in Hematology · doi:10.1155/2022/6831640 · Cited by 6 · see citing works

The time between vaccination and infection impacts immunity against SARS-CoV-2 variantsPreprint

Bates, T. A., Leier, H. C., McBride, S. K., Schoen, D., Lyski, Z. L., Lee, D. X., Messer, W. B., Curlin, M. E., & Tafesse, F. (2023) · medRxiv · doi:10.1101/2023.01.02.23284120 · Cited by 6 · see citing works

Current Challenges and Solutions for Clinical Management and Care of People with HIV: Findings from the 12th Annual International HIV and Aging Workshop

Yu, X., Lobo, J. D., Sundermann, E. E., Baker, D. J., Tracy, R. P., Kuchel, G. A., Stephenson, K. E., Letendre, S. L., Brew, B. J., Cysique, L. A., et al. (2022) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2022.0079 · Cited by 5 · see citing works

Seroprevalence of Anti-S1-RBD Antibodies in Pre-pandemic and Pandemic Subjects From Hail Region, KSA

Sherwani, S., Khan, M. W. A., Mallik, A., Khan, M., Saleem, M., Raafat, M., Shati, A. A., & Alam, N. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.874741 · Cited by 4 · see citing works

Age- and sex-based changes in spike protein antibody status after SARS-CoV-2 vaccination and effect of past-infection in healthcare workers in Osaka

Hoshida, S., Koeda, N., Hattori, H., Tanaka, M., Tanaka, I., Fukui, H., Fujita, J., Sasaki, Y., & Tamura, S. (2022) · BMC Infectious Diseases · doi:10.1186/s12879-022-07695-7 · Cited by 4 · see citing works

Age-Related Differences in Neutralizing Antibody Responses against SARS-CoV-2 Delta and Omicron Variants in 151 SARS-CoV-2-Naïve Metropolitan Residents Boosted with BNT162b2

Lee, B., Bae, G. E., Jeong, I. H., Kim, J., Kwon, M., Kim, J., Kim, B., Lee, J.-W., Nam, J.-H., Huh, H. J., et al. (2024) · The Journal of Applied Laboratory Medicine · doi:10.1093/jalm/jfae014 · Cited by 3 · see citing works

Benefits of Repeated SARS-CoV-2 Vaccination and Virus-induced Cross-neutralization Potential in Immunocompromised Transplant Patients and Healthy Individuals

Hauser, D., Urda, L., Lang, C. M. R., Mittelholzer, C., Otte, F., Kipfer, E. T., Zhang, Y., Lett, M. J., Schebitz, C., Müller, R., et al. (2024) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofae527 · Cited by 3 · see citing works

Correlation of SARS-CoV-2 Neutralization with Antibody Levels in Vaccinated Individuals

Chowdhury, S. H., Riley, S., Mikolajczyk, R., Smith, L. N., Suresh, L., & Jacobs, A. (2023) · Viruses · doi:10.3390/v15030793 · Cited by 3 · see citing works

Year 3 of COVID-19: Harsh Truths, Brutal Realities, and Glimmers of Hope

Poland, G. A., Issa, M., & Sundsted, K. K. (2022) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2022.10.022 · Cited by 3 · see citing works

Antibody titers among healthcare workers for coronavirus disease 2019 at 6 months after BNT162b2 vaccination

Kurashima, K., Numano, T., Yoshino, A., Osawa, A., Takaku, Y., Kagiyama, N., & Yanagisawa, T. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.08.035 · Cited by 2 · see citing works

Clinical Features and Outcomes of Hospitalized Adult Patients With Breakthrough COVID-19 Infections: A Propensity-Score–Matched Observational Study

Niu, J., Samuels, S. K., Sareli, C., Mayer, D., Visbal, A., & Sareli, A. E. (2023) · American Journal of Epidemiology · doi:10.1093/aje/kwad199 · Cited by 2 · see citing works

Characterization of SARS-CoV-2-specific humoral immunity and associated factors in the healthy population post-vaccination

Zhan, X.-Y., Chen, Y., Zhang, X., Shi, Q., Chen, K., Zeng, C., Zhang, Y., Liang, Y., Li, W., Li, M., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.12.021 · Cited by 2 · see citing works

Post-vaccination SARS-cov-2 infection in nursing home residents, Bordeaux, France

Lartigau, M., Ouattara, E. N., Tumiotto, C., Wodrich, H., Busson, L., Trimoulet, P., Thiel, E., Nouzille, M., Dubos, M., Lafon, M., et al. (2022) · Journal of Clinical Virology · doi:10.1016/j.jcv.2022.105134 · Cited by 2 · see citing works

Humoral Immune Responses following COVID-19 Vaccinations among Adults in Tanzania

Bakari, M., Aboud, S., Kasubi, M. J., Mmbando, B. P., Ntinginya, N. E., Sichalwe, A. W., Ubuguyu, O., Magesa, A. S., Rutananukwa, N. L., Nyawale, H. A., et al. (2023) · Vaccines · doi:10.3390/vaccines12010022 · Cited by 2 · see citing works

Kinetics and Factors Associated With 12-Month Persistence of Neutralizing Antibody Induced by Two Inactivated COVID-19 VaccinesPreprint

Wang, F.-Z., Huang, B., Lv, H., Feng, L., Ren, W., Wang, X., Tang, L., Liu, Q., Wu, D., Zheng, H., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4065610 · Cited by 2 · see citing works

SARS-CoV-2 Immunization Index in the Academic Community: A Retrospective Post-Vaccination Study

Oliveira, K., Almeida, A., Silva, C., Brito, M., & Ribeiro, E. (2024) · Infectious Disease Reports · doi:10.3390/idr16060088 · Cited by 1 · see citing works

Pre‐Existing Th1 Immunity Outperforms Age in Predicting Antibody Responses to SARS‐CoV‐2 Inactivated Vaccines

Ye, C., Zhang, X., Qiu, L., Ji, J., Gu, J., Jia, H., Lu, Y., Chen, J., Meng, Z., Lian, J., et al. (2025) · Advanced Science · doi:10.1002/advs.202514147 · Cited by 1 · see citing works

Immunogenicity of a recombinant subunit COVID-19 vaccine: A prospective, multi-centre, longitudinal study in Chinese Alzheimer’s disease patients

Weng, Y., Huang, Y., Zhang, J., Wu, Y., He, Q., Litchev, S., Wu, A., Ling, Z., Zhao, N., Liao, R., et al. (2025) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2025.2591504 · Cited by 1 · see citing works

Exclusion by design: enrollment criteria limit older adult participation in SARS-CoV-2 vaccine clinical trials

Johnson, T. N., Chu, H. Y., & Fohner, A. E. (2026) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2026.112343 · Cited by 1 · see citing works

Adoptive T-cell therapies to overcome T cell-dependent immune dysregulations in COVID-19

Taş, S. K., Uzunoğlu, M. S., Uzunoğlu, A. S., Kırkık, D., Altunkanat, D., & Kalkanli, N. (2022) · TURKISH JOURNAL OF BIOLOGY · doi:10.55730/1300-0152.2579 · Cited by 1 · see citing works

Cellular and Antibody Immunity after COVID-19 Vaccination at >4-Month Follow Up in Immunocompetent and Immunocompromised SubjectsPreprint

Sindhi, R. K., Ashokkumar, C., Singh, V. M. N. D., Spishock, B., Saunders, M., Mabasa, A., Sindhi, E., Sethi, P., Reddy, A. P., Subramaniam, S., et al. (2021) · medRxiv · doi:10.1101/2021.10.07.21257459 · Cited by 1 · see citing works

Contrasting Effects of SARS-CoV-2 Vaccination vs. Infection on Antibody and TCR RepertoiresPreprint

Braun, J., Hill, E. D., Contreras, E., Yasuda, M., Morgan, A., Ditelberg, S., Winter, E., Callahan, C. J., Mazzoni, G., Kirmaier, A., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.09.08.556703 · Cited by 1 · see citing works

Neutralizing antibody responses and cellular responses against SARS-CoV-2 Omicron subvariant BA.5 after mRNA SARS-CoV-2 vaccination in kidney transplant recipientsPreprint

Kawashiro, K., Suzuki, R., Nogimori, T., Iwahara, N., Hirose, T., Okada, K., Yamamoto, T., Fukuhara, T., Hotta, K., & Shinohara, N. (2024) · Research Square · doi:10.21203/rs.3.rs-3857039/v1 · Cited by 1 · see citing works

Effectiveness of Vaccination against Reported SARS-CoV-2 Infection in United States Coast Guard Personnel between May and August 2021: A Time-Series AnalysisPreprint

Iskander, J. K., Frost, J., Russell, S., Ahluwalia, J. S., Ward, E., Steiner, S., Thomas, D. L., & Michaud, P. R. (2021) · medRxiv · doi:10.1101/2021.11.19.21266537

Ne pas renoncer à l’immunité collective

(2021) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2021.09.011

Adoptive T-cell therapies to overcome T cell-dependent immune dysregulations in COVID-19

Taş, S. K., Uzunoğlu, M. S., Uzunoğlu, A. S., Kırkık, D., Altunkanat, D., & Kalkanli, N. (2021) · TURKISH JOURNAL OF BIOLOGY · doi:10.3906/biy-2109-85 · Cited by 1 · see citing works

Longitudinal monitoring of SARS-CoV-2 neutralizing antibody titers and its impact on employee personal wellness decisionsPreprint

Vandergaast, R., Carey, T. S., Suksanpaisan, L., Lathrum, C., Narjari, R., Haselton, M., Schnebeck, L., Wijesekara, A., Duncan, A., Russell, L., et al. (2022) · medRxiv · doi:10.1101/2022.03.01.22271202

Age- and sex-based changes in spike protein antibody status after SARS-CoV-2 vaccination and effect of past-infection in healthcare workers in OsakaPreprint

Hoshida, S., Koeda, N., Hattori, H., Tanaka, M., Tanaka, I., Fukui, H., Fujita, J., Sasaki, Y., & Tamura, S. (2022) · Research Square · doi:10.21203/rs.3.rs-1751845/v1

Adverse Effects Post COVID-19 Vaccination and its Association with Age, Gender and Comorbid Disease in Basrah City Southern of Iraq

Abdul-nabi, Z. N., Mohammed-Jawad, N. K., Fareed, N. Y., Neamah, N. F., & Shari, F. H. (2023) · Current Drug Safety · doi:10.2174/1574886318666230525142152

Differential antibody response to COVID-19 disease and COVID-19 vaccines

Şenol, F. F., Bahçeci, İ., Mercantepe, F., İbik, Y. E., Timurkaan, E. S., Toraman, Z. A., Aytaç, Ö., Öner, P., & Şenol, A. (2023) · International Journal of Research in Medical Sciences · doi:10.18203/2320-6012.ijrms20231595

Sex and Age

Lundberg, G. P., Toleva, O., & Cutchins, A. C. (2023) · JACC Advances · doi:10.1016/j.jacadv.2023.100325

How many is good enough? An analysis of serological follow-up after vaccination against SARS-CoV-2

Stępień, M., Zalewska, M., Kuźniarski, A., Jankowska‐Polańska, B., Piwowar, A., Świątoniowska-Lonc, N., & Knysz, B. (2023) · Postępy Higieny i Medycyny Doświadczalnej · doi:10.2478/ahem-2023-0020

ĐÁP ỨNG MIỄN DỊCH SAU TIÊM MŨI 4 VACXIN NGỪA COVID-19 Ở BỆNH NHÂN SUY THẬN MẠN GIAI ĐOẠN CUỐI ≥60 TUỔI

Nguyễn, N. N., Huỳnh, M. G., & Tân, H. N. (2023) · Tạp chí Y Dược học Cần Thơ · doi:10.58490/ctump.2023i69.1996

Persistence of Antibody Response Against SARS-CoV-2 After Vaccination

Bekti, H. S., Habibah, N., Dharmawati, I. G. A. A., Merdekawati, F., & Noviar, G. (2023) · JURNAL INFO KESEHATAN · doi:10.31965/infokes.vol21.iss4.1066

Emerging Omicron Subvariants EG.5 and BA.2.86: Implications for COVID-19 Immunity and SurveillancePreprint

Hamraa, J., Khidri, F. F., Saeed, S., Oni, O. E., Anbreen, S., & Shaukat, S. (2024) · Qeios · doi:10.32388/8ujc2t

Emerging Omicron Subvariants EG.5 and BA.2.86: Implications for COVID-19 Immunity and SurveillancePreprint

Hamraa, J., Khidri, F. F., Saeed, S., Oni, O. E., Anbreen, S., & Shaukat, S. (2024) · Qeios · doi:10.32388/8ujc2t.2

Enhanced immunogenicity of SARS-CoV-2 antigen with aluminum adjuvant and polysaccharide nucleic acid fraction of Bacillus Calmette Guerin

Ji, J., Zhu, M., Zhu, L., Liu, Z., Yang, S., Tang, T.-M., Wu, Z., Shi, D., Zhang, J., Zhang, X., et al. (2025) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2025.107578

Prospective Evaluation of Antibody Response post COVID-19 vaccination in older persons ≧ 60 years old (PEARL 60): A longitudinal 15-months study in a tertiary centre in Malaysia

Hasmukharay, K., Verma, A. K., Aravindhan, K., Alagappan, P. R. S., Kamal, A. K. M., Zulhaimi, N. S., Saedon, N. I., Sam, J. I.-C., Pin, T. M., & Rajasuriar, R. (2026) · PLoS ONE · doi:10.1371/journal.pone.0340891

Contrasting effects of SARS-CoV-2 vaccination vs. infection on antibody and TCR repertoires

Braun, J., Hill, E. D., Contreras, E., Yasuda, M., Morgan, A., Ditelberg, S., Winter, E., Callahan, C. J., Mazzoni, G., Kirmaier, A., et al. (2026) · PLoS ONE · doi:10.1371/journal.pone.0343939

SARS-CoV-2 Infection and COVID-19 Vaccine Antibody Responses in Two Canadian Cohorts of Persons Living with HIV

Walmsley, S. L., Lovblom, L. E., Boyachuk, B., Cooper, C., Martel‐Laferrière, V., Loutfy, M. R., Vachon, M.-L., Haider, S., Aldebes, P., Colwill, K., et al. (2026) · Antibodies · doi:10.3390/antib15020030

Adenosine deaminase co-immunization reverses age-associated immunosenescence by restoring germinal center T follicular helper cell functionPreprint

Bitsko, E. N., Joyner, D., Maslanka, J. R., Woloszczuk, K., Edgerton, A. O., Bell, M. R., Sell, C., Alameh, M., Beld, J., Haddad, E. K., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.04.730208

Age-Related Differences in Neutralizing Antibody Responses against SARS-CoV-2 Delta and Omicron Variants in 151 SARS-CoV-2-Naïve Metropolitan Residents Boosted with BNT162b2

Lee, B., Bae, G. E., Jeong, I. H., Kim, J., Kwon, M., Kim, J., Kim, B., Lee, J.-W., Nam, J.-H., Huh, H. J., et al. (2024) · The Journal of Applied Laboratory Medicine · doi:10.1093/jalm/jfae014 · Cited by 3 · see citing works

Age-Dependent Reduction in Neutralization against Alpha and Beta Variants of BNT162b2 SARS-CoV-2 Vaccine-Induced Immunity

Kawasuji, H., Morinaga, Y., Tani, H., Saga, Y., Kaneda, M., Murai, Y., Ueno, A., Miyajima, Y., Fukui, Y., Nagaoka, K., et al. (2021) · Microbiology Spectrum · doi:10.1128/spectrum.00561-21 · Cited by 24 · see citing works

Assessment of Neutralizing Antibody Response Against SARS-CoV-2 Variants After 2 to 3 Doses of the BNT162b2 mRNA COVID-19 Vaccine

Furukawa, K., Tjan, L. H., Kurahashi, Y., Sutandhio, S., Nishimura, M., Arii, J., & Mori, Y. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.10780 · Cited by 45 · see citing works

Neutralizing antibody activity against 21 SARS-CoV-2 variants in older adults vaccinated with BNT162b2

Newman, J., Thakur, N., Peacock, T. P., Bialy, D., Elrefaey, A. M. E., Bogaardt, C., Horton, D. L., Ho, S., Kankeyan, T., Carr, C., et al. (2022) · Nature Microbiology · doi:10.1038/s41564-022-01163-3 · Cited by 85 · see citing works

BNT162b2 Vaccination Elicits Strong Serological Immune Responses Against SARS-CoV-2 Including Variants of Concern in Elderly Convalescents

Jahrsdörfer, B., Fabricius, D., Scholz, J. A. M., Ludwig, C., Grempels, A., Lotfi, R., Körper, S., Adler, G., & Schrezenmeier, H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.743422 · Cited by 9 · see citing works